Journal article 4 views
Finerenone in the management of diabetes kidney disease
Parijat De,
May T Khine,
Andrew Frankel,
Gabrielle Goldet,
Debasish Banerjee,
Rosa M Montero,
Tahseen A Chowdhury,
Damien Fogarty,
Janaka Karalliedde,
Ritwika Mallik,
Dipesh C Patel,
Mona Wahba,
Peter Winocour,
Sagen Zac-Varghese,
Steve Bain 
,
Adnan Sharif,
Srikanth Bellary,
Indranil Dasgupta
,
Adnan Sharif,
Srikanth Bellary,
Indranil Dasgupta
BMC Nephrology, Volume: 26, Issue: 1
Swansea University Author:
Steve Bain
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.1186/s12882-025-03985-9
Abstract
People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular...
| Published in: | BMC Nephrology |
|---|---|
| ISSN: | 1471-2369 |
| Published: |
Springer Science and Business Media LLC
2025
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa68787 |
| Abstract: |
People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular disease. Slowing progression of kidney disease and reducing cardiovascular events can be achieved by a number of means including the targeting of blood pressure and the use of specific classes of drugs The use of Renin Angiotensin Aldosterone System (RAAS) blockade is effective in preventing or slowing progression of DKD and reducing cardiovascular events in people with type 2 diabetes, albeit differently according to the stage of DKD. However, emerging therapy such as non-steroidal selective mineralocorticoid antagonists (finerenone) is proven to lower blood pressure and further reduce the risk of progression of DKD and cardiovascular disease in people with type 2 diabetes. This consensus reviews current evidence and make recommendations for the use of finerenone in the management of diabetes kidney disease in the UK. |
|---|---|
| Keywords: |
Diabetes; Hypertension; Albuminuria; Diabetic kidney disease; Finerenone; ACE inhibitors; Angiotensin receptor blockers; Renin Angiotensin Aldosterone System (RAAS) |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Issue: |
1 |